SUNY-Upstate Is Part of National Trial Evaluating Drug to Slow Alzheimer's Disease
September 13, 2019
September 13, 2019
SYRACUSE, New York, Sept. 13 [TNSmedicalresearch] -- The State University of New York's Upstate Medical University Campus issued the following news:
Upstate Medical University is now screening participants in a new, national Alzheimer's disease (AD) clinical research study evaluating the potential benefits of an investigational medicine for people with mild-to-moderate AD.
The Phase 2/3 study, called T2 Protect AD, is evaluating the investigational drug troriluzole (BHV . . .
Upstate Medical University is now screening participants in a new, national Alzheimer's disease (AD) clinical research study evaluating the potential benefits of an investigational medicine for people with mild-to-moderate AD.
The Phase 2/3 study, called T2 Protect AD, is evaluating the investigational drug troriluzole (BHV . . .